Kangmei Pharmaceutical Co Ltd operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Kangmei Pharmaceutical Co Ltd with three other
companies in this sector in China:
Apeloa Pharmaceutical Co Ltd
sales of 4.77 billion Chinese Renmimbi [US$738.42 million]
of which 100%
was Health Care & Pharmaceutical),
Zhejiang Nhu Co Ltd
(4.70 billion Chinese Renmimbi [US$726.98 million]
of which 96%
was Pharmaceutical Chemicals), and
China Resources Double-Crane Pharmaceutical Company Limited
(5.49 billion Chinese Renmimbi [US$850.23 million]
of which 62%
was Non- transfusion).
Kangmei Pharmaceutical Co Ltd reported sales of 21.61 billion Chinese Renmimbi (US$3.35 billion)
December of 2016.
increase of 19.8%
versus 2015, when the company's sales were 18.03 billion Chinese Renmimbi.
Sales at Kangmei Pharmaceutical Co Ltd have increased during each of the previous five years
(and since 2011, sales have increased a total of 255%).
Sales of Other (Main) saw an increase
that was more than double the company's growth rate: sales were up
1,198.2% in 2016, from
72.65 million Chinese Renmimbi to 943.17 million Chinese Renmimbi.
Not all segments of Kangmei Pharmaceutical Co Ltd experienced an increase in sales in 2016:
sales of Other Operation fell 89.7% to 66.58 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).